X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison

    The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

    NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

    NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    FDA Clears Novavax COVID-19 Vaccine As Fourth Option In US

    Australia Creates A Novel Stem Cell Production Technique

    Australia Creates A Novel Stem Cell Production Technique

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    Bispecific Blood Cancer Drug By Roche Globally Approved

    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison

    The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

    NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

    NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    FDA Clears Novavax COVID-19 Vaccine As Fourth Option In US

    Australia Creates A Novel Stem Cell Production Technique

    Australia Creates A Novel Stem Cell Production Technique

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

    Bispecific Blood Cancer Drug By Roche Globally Approved

    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

Content Team by Content Team
18th July 2022
in Clinical Trials, News
NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

An early-stage clinical trial assessing an investigational vaccine to stave off Nipah virus infection has been started by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Produced by Moderna, Inc. in Cambridge, Massachusetts, the experimental vaccine was developed in collaboration with the NIAID’s Vaccine Research Center. It is centred around a messenger RNA (mRNA) platform, a technology that is present in a number of licenced COVID-19 vaccines. The Phase 1 clinical trial, which is being carried out at the NIH Clinical Center in Bethesda, Maryland, is being funded by NIAID.

The Nipah virus infection is a zoonotic disease, which means that it can pass from animal to human. The fruit bat serves as the ideal host for the virus. There were 265 human cases and 105 fatalities as a result of the first recorded Nipah outbreak, which struck Malaysia and Singapore in 1998. The outbreak also significantly harmed the local swine sector economically. Annual outbreaks have been happening in Asia since 1999, mostly in Bangladesh and India. The virus can quickly develop from signs of a respiratory infection to encephalitis (brain swelling), which can result in a coma or death. According to estimates, between 40 and 75% of Nipah virus victims pass away. Although person-to-person transmission is rare, the majority of cases are spread by animals. There is currently no approved vaccination or treatment for Nipah virus infection.

According to NIAID Director Anthony S. Fauci, M.D., Nipah virus poses a significant pandemic threat because it mutates very swiftly, causes disease in a wide range of mammals, can be transferred from person to person, and kills a substantial proportion of the people it infects. A preventive Nipah virus vaccination is urgently needed.

The Pandemic Preparedness Plan from the NIAID, which was released earlier this year, built a system for studying viruses with pandemic potential and gave prototype pathogens like the Nipah virus top priority in research. This is the first clinical experiment using the prototype pathogen method since it was published.

In 40 healthy people between the ages of 18 and 60, the investigational mRNA-1215 Nipah virus vaccine will be put to the test in a drug concentration clinical trial to determine its safety, acceptability, and capacity to elicit an immunological response. In particular, the investigational vaccine will be administered in two doses by injection into the shoulder muscle, four or 12 weeks apart, to 4 groups of 10 people each. Group 1 (10 participants) shall receive two injections of 25 micrograms (mcg). Group 2 will receive two injections of 50 mcg, and Group 3 will get two injections of 100 mcg, all administered four weeks apart. An interim review of the outcomes from the three prior groups will be used to establish the vaccination dose for the fourth group of participants. Two injections will be given to the fourth group, separated by 12 weeks. Participants in the study will be assessed during the course of the investigation through clinical assessment and blood sampling, and they will be monitored by clinical study staff for 52 weeks after receiving their final immunisation.

Previous Post

Could The Long Deckline In Biotechnology M&A Be Ending

Next Post

The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

Related Posts

Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Manufacturing

The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Health & Nutrition

Acute Allergies To Novavax COVID Jabs Get Listed By The EU

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
Featured

As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

14th July 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
FDA Approvals

FDA Clears Novavax COVID-19 Vaccine As Fourth Option In US

14th July 2022
Next Post
Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison

The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

Latest News

Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Manufacturing

The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

18th July 2022
NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine
Clinical Trials

NIH Initiates Clinical Study of mRNA Nipah Virus Vaccine

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Health & Nutrition

Acute Allergies To Novavax COVID Jabs Get Listed By The EU

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In